findmyKOL
Clinical trialNCT07265674RecruitingPhase 3Interventional

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

SponsorJ-Pharma Co., Ltd.Enrollment480Advanced Biliary Tract CancerBiliary Tract Cancer (BTC)
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

18 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • City of Hope (site 107)

    Duarte, California, United States

    Recruiting
  • University of California at Irvine (site 101)

    Orange, California, United States

    Recruiting
  • Ucla Medical Center (site 117)

    Santa Monica, California, United States

    Not, yet, recruiting
  • Moffitt Cancer Center Magnolia Campus (site 123)

    Tampa, Florida, United States

    Recruiting
  • City of Hope - Chicago Cancer Center (site 128)

    Zion, Illinois, United States

    Recruiting
  • Norton Cancer Institute (site 115)

    Louisville, Kentucky, United States

    Recruiting
  • Ochsner Medical Center (site 120)

    New Orleans, Louisiana, United States

    Not, yet, recruiting
  • Karmanos Cancer Center (site 109)

    Detroit, Michigan, United States

    Recruiting
  • Masonic Cancer Center, University of Minnesota (site 116)

    Minneapolis, Minnesota, United States

    Recruiting
  • Comprehensive Cancer Centers of Nevada - Central Valley (site 124)

    Las Vegas, Nevada, United States

    Recruiting
  • Rutgers Cancer Institute of New Jersey (site 103)

    New Brunswick, New Jersey, United States

    Recruiting
  • Rosewell Park Comprehensive Cancer Center (site 114)

    Buffalo, New York, United States

    Not, yet, recruiting
  • Memorial Sloan Kettering Cancer Center (site 108)

    New York, New York, United States

    Recruiting
  • University Hospitals Cleveland Medical Center Seidman Cancer Center (site 111)

    Cleveland, Ohio, United States

    Recruiting
  • James Cancer Hospital and Solove Research Institute (site 119)

    Columbus, Ohio, United States

    Recruiting
  • Mercy Clinic (site 110)

    Oklahoma City, Oklahoma, United States

    Recruiting
  • University of Texas Southwestern Medical Center (site 104)

    Dallas, Texas, United States

    Recruiting
  • Fred Hutchinson Cancer Center Clinic (site 122)

    Seattle, Washington, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 May 2026
Primary completion
31 Oct 2027
Completion
31 Oct 2027
Last update posted
1 Jul 2026
Registered enrollment
480
Registry id
NCT07265674

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.